Work

Figure S2 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Year: 2023

Type: other

Abstract: Figure S2 - PDF 22K, C-reactive protein (CRP) and gamma M-spike levels in a patient with light-chain multiple myeloma who received siltuximab 12 mg/kg q3w and had confirmed complete response lasting >12 months

DOI: 10.1158/1078-0432.22451118.v1

Authors: Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Z. Usmani, Helgi van de Velde, Xiang Qin, Thomas A. Puchalski, Brett Hall, Manjula Reddy, Ming Qi, Frits van Rhee

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361908683

Cites:

Cited by:

Related to: 10